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Aim: The aim of this investigation is to determine the degree of tumor regression by
histopathological evaluation of surgical specimen after neoadjuvant chemo-radiotherapy
for patients with stage IIIB rectal cancer.
Background: The standard therapy for rectal carcinoma is surgical, however, preoperative
radiochemotherapy will play an increasing role especially in locally advanced disease. To
estimate the prognosis and the effect of radiochemotherapy the postradiochemotherapeu-
tical pathological features are important to assess.
Materials and methods: Ten patients with cT3–4, cN1 stage rectal cancer received preoper-
ative chemo-radiotherapy. A total tumor dose of 50Gy was applied to all patients, with a
daily fraction of 2Gy, 5 times a week, with concomitant Capecitabine 1650mg/m2. A path-
omorphologic assessment of the therapeutic response of the residual tumor volumes and
estimation of tumor control were performed using Dworak’s system of tumor regression
grading (TRD) from no regression (0) to a complete tumor control (4).
Results:Dworak’s TRD for the examinedpatients is as follows: in 20%of the patients no tumor
regression was observed – Grade 0, in 30% – Grade 1, in 20% – Grade 2 and in 30% a complete
tumor regression was achieved – Grade 4. Four of the patients (40%) presented with bor-
derline resectable tumors before the neoadjuvant chemo-radiotherapy. Nine of the patients
(90%) underwent radical surgery. In one case (10%) a radical surgery was not possible. One
patient (10%) developed severe radiation enteritis in both the early and late postoperative
period, with her tumor regression evaluated as Grade 4.
Conclusion:Accurate evaluation of local tumor control usingDworak’s tumor regression grad-ing scale after preoperative chemo-radiotherapy gives the basis for a larger investigation and
search for a correlation with the prognosis of the disease and individual choice of adjuvant
treatment.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.∗ Corresponding author.
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507-1367/$ – see front matter © 2011 Greater Poland Cancer Centre, Poland
oi:10.1016/j.rpor.2011.06.008z.o.o. All rights reserved.. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
d rad238 reports of practical oncology an
1. Introduction
Neoadjuvant treatment is the standard of care for locally
advanced rectal carcinoma. The use of combined preopera-
tive chemo-radiotherapy in the management of patients with
locally advanced rectal carcinoma with stage cT3–4, cN1 and
M0has been shown to improve the yearly relapse-free survival
with 46% compared to a group treated with surgery alone.1
Histological investigation of the primary tumor at diagno-
sis and of the surgical specimen is a key for assessing the
therapeutic response to the chemo-radiotherapy and surgical
treatment.
The predominant colloid changes observed after preoper-
ative radiotherapy have been ﬁrst described by Dworak et al.2
The author recommends speciﬁc standards for pathomorpho-
logic workup of the specimens after neoadjuvant treatment
and thedegrees of tumor response for rectal carcinoma.Tumor
regression grading (TRG) described by Dworak begins with 0
indicating no tumor regression and rises up to 4 referring to
total tumor regression:
Grade 0: No tumor regression;
Grade 1: Dominant tumor mass with obvious ﬁbrosis and/or
vasculopathy;
Grade 2: Dominantly ﬁbrotic changes with few tumor cells or
groups;
Grade 3: Very few (difﬁcult to ﬁnd microscopically) tumor
cells in ﬁbrotic tissue;
Grade 4: No tumor cells, only ﬁbrotic mass (total tumor
regression or response).
A simpler version of the grading can be used in clinical
practice:
(1) Weak pathomorphologic response: no tumor regression:
dominant ﬁbrotic changes with few tumor cells or groups
of tumor cells (Dworak 0–2).
(2) Excellent pathomorphologic response: good tumor regres-
sion: very few (difﬁcult to ﬁndmicroscopically) tumor cells
in ﬁbrotic tissue with or without mucin or total tumor
regression (Dworak 3–4).
Dworak’s grading system for tumor regression is mainly
used in Europe. It has been modiﬁed by Ryan in 20053 so that
full tumor response is deﬁned as 0:
• 0 – full tumor regression, no visible tumor cells;
• 1 – moderate tumor regression, very few or small groups of
tumor cells;
• minimal tumor regression, residual tumor in ﬁbrotic tissue;
• no tumor regression, residual tumor without any signs of
destroyed tumor cells.
Current recommendations of the NCCN Rectal Cancer
Guidelines Panel 20114 follow theAmerican systemof Ryan for
evaluating the degree of tumor regression after neoadjuvant
treatment.
Results of clinical investigations using Dworak’s scale have
shown that TRG as a measure of the response to preoper-iotherapy 1 6 ( 2 0 1 1 ) 237–242
ative treatment correlates very precisely with the observed
relapse-free and overall survival.5 Shia et al.6 consider that
the degree of reduction of preoperative T and N stage and
limphovascular invasion statistically correlate with relapse-
free survival (p=0.002). Additional morphological features
have been found to correlate with the reduction of relapse-
free survival, independent of other risk factors: type of stromal
response, inﬂammation inﬁltrates (p=0.001) and lack of super-
ﬁcial ulcerations (p=0.026). Thesemorphologic characteristics
are subject to additional investigations and analysis. Different
authors report that full pathomorphologic remission corre-
lates with an improved 3-year survival rate.7–9
That is why, we thought it useful to fully investigate
the histopathologic changes observed after treatment using
Dworak’s scale for tumor regression grading (TRG).
2. Background
Residual tumor after surgical therapy of rectal cancer is one of
the most important prognostic factors. Therefore, the major
goal of therapy is a curative resection. Large tumors with
invasion of adjacent structures (e.g. pelvic wall, urinary blad-
der, prostate) may be, however, not completely resectable.
Radiochemotherapy has been described as a useful tool for
the reduction of tumor mass.
3. Materials and methods
In the period between 2008 and 2010, 10 patients with locally
advanced rectal carcinoma stage cT3, cT4 and cN1 were
treated at the Radiotherapy Clinique. Rectoscopy, endorec-
tal ultrasonography and CT of the abdomen and pelvis were
used to stage the patients preoperatively. All the patients
received preoperative chemo-radiotherapy to a total dose of
50Gy, 2Gy a day, ﬁve times a week, with a concomitant
daily oral intake of Capecitabine 1650mg/m2 (an average of 6
tablets at night). The treatment planningwas done using com-
puter tomography after bowl contrasting with an oral agent
and the patient scanned in prone position. Clinical target
volume (CTV) included the primary tumor and the regional
pelvic lymph nodes—upper, middle and lower rectal, lower
mesenterial, obturator, internal iliac up to the bifurcation
of arteria iliaca communis, mesorectal, lateral sacral, pre-
sacral, and sacral promontorial. External iliac lymph nodes
were included only in patients with T4 tumors inﬁltrating
neighboring organs—the bladder, prostate, female genitalia.
In patients with lower situated tumors, below linea dentata,
the inguinal lymph nodes were also included. Planned target
volume (PTV)—included the CTV with 1 cm margin. Patients
were irradiated using three or four ﬁeld technique and the
dose in the small intestines was not higher than the toler-
ated 40–45Gy. All patients were operable and only one surgery
ended with positive margins—R1 resection.
Evaluation of the degree of tumor regression was per-
formed and the following pathomorphologic changes of the
surgical specimens and regional lymph nodes were inves-
tigated in detail: size of the tumor, tumor invasion, grade
of tumor differentiation (G), lymphovascular invasion (LVI),
state of resection margins and response to the preopera-
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ive treatment—Dworak’s TRG. The basic rules followed by
he pathomorphologists working with the surgical specimens
ere:
After surgery the pathomorphologic material is sent for
nvestigation together with the medical history (anamnesis),
he cTNM stage, type of surgery performed, type of preopera-
ive treatment (chemo-radiotherapy or radiotherapy alone).
The surgical specimen is examined by the pathologist who
etermines tumor topography (Fig. 1), evaluates the quality of
esorectal excision and examines the periphery, the proximal
nd distal resection margins.
The description of the examining pathologistmust include:
istological type of the tumor: adenocarcinoma, colloid carci-
oma, squamous cell carcinoma; the degree of malignancy:
ell differentiated G1, moderately differentiated G2, low dif-
erentiated G3 and undifferentiated G4; LVI; lateral, distal and
roximal resection margins; number of regional lymph nodes
xamined; number ofmetastatic lymph nodes; pathomorpho-
ogic response grade.
Lymph node dissection is performed to thoroughly exam-
ne the meso of the rectum. As many lymph nodes as
ossible should be submitted for microscopic investigation to
etermine the postoperative stage of the disease. Meticulous
icroscopic examinationof the lymphnodes identiﬁedduring
ross examination, as well as all tissue suspicious for metas-
asis should be performed. Even if there is no residual tumor in
Table 1 – .
Histological type G usT ctT yR ypT GT
1 Adenoca. 2 3 3 0 2 1
2 Adenoca. 3 4 4 1 4 0
3 Adenoca. 3 3 3 0 0 4
4 Mucinous adenoca. 2 3 2 0 2 2
5 Mucinous adenoca. 3 3 3 0 0 4
6 Adenoca. 2 0 4 0 3 2
7 Adenoca. 2 2 3 0 0 4
3 Adenoca. 3 4 4 0 4 0
9 Adenoca. 2 3 3 0 2 1
10 Adenoca. 3 0 4 0 3 1
Histological type, grade, depth of inﬁltration and lymph node status by e
Clinical stages before radiochemotherapy and UICC stages after surgery. P
surgery and pathological examination and lymph vascular invasion (LVI).e circumferential border—invasion of the tumor (b).
the rectal wall, theremay be residualmalignancy in the lymph
nodes and therefore they should be thoroughly examined.
Staging of rectal cancer was performed according to the
UICC system (1993)10, with the “y” symbol identifying the
cases following initial chemo-radiotherapy anddifferentiating
them from the cases with no initial treatment. Determination
of the depth of invasion and lymph node status were used
for estimation of the effectiveness of preoperative chemo-
radiotherapy. Clinical T staging was deﬁned with usT when
endorectal sonography was used for the initial diagnosis and
with ctT when CT was used. Similarly, the status of the lymph
nodeswas deﬁned as usN and ctN. Histologic evaluation of the
surgical specimen following neoadjuvant treatment adds the
symbol “y” for the primary tumor ypT and the regional lymph
nodes ypN.
4. Results
Histologic changes following radiotherapy or chemo-
radiotherapy were characterized not only by the existence or
absence of tumor invasion in depth of the rectal wall, ypT,
but also by the type of necrosis, ﬁbrosis, speciﬁc vascular
and cellular changes, not recognized in the tumors without
neoadjuvant treatment, deﬁned by Dworak’s TRG.
R Dworak usN ctN ypN cTHM pTNM LVI
1 1 0 IIIB I No
0 1 0 IIIB IB Yes
1 1 0 IIIB 0 No
1 1 1 IIIB ETA No
1 1 1 IIIB 0 No
0 1 0 IIIB IIA Yes
1 1 0 IIIA 0 No
1 1 0 IIIB IB Yes
0 1 0 IIIB I No
0 1 0 IIIB IIA No
ndosonography, CT and the pathologist (Tus, Tct, pT; Nus, Nct, pN).
resence (local and distant) or absence (yR0) of residual tumor after
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Fig. 2 – Morphologic features after radiochemotherapy with residual tumor cells.Thehistologic type of the tumor for all patients is presented
in Table 1, with 80% of the patients having adenocarcinoma
and the rest, mucinous adenocarcinoma. The degree of malig-
nancy of the tumor (G) showed that 50% of the cases were
undifferentiated carcinoma G3 and 50% were moderately dif-
ferentiated carcinoma G2. The depth of tumor inﬁltration,
assessed by endorectal ultrasonography, usT, fully correlated
with the ctT deﬁned by CT.
Four of the patients (40%) were borderline operable before
the preoperative chemo-radiotherapy. In 90% of the cases,
radical surgery was managed and in only one patient posi-
tive margins were found—R1 resection. Four patients (40%)
underwent Miles’s rectal amputation, the other 60%, had
sphincter-preserving surgeries—frontal or lower resection.
Histological veriﬁcation of the surgical specimens and eval-
uation of the depth of tumor inﬁltration after the neoadjuvant
treatment and surgery showed tumor regression in 80% of the
patients. In 3 patients (30%), all with pretreatment usT3, full
tumor control was achieved—ypT0. In 50%5 of the patients,
partial tumor regression was achieved, three regressed from
usT3 to ypT2 and two from usT4 to ypT3. No change was
observed in 2 patients (20%) with usT4.
According to Dworak’s deﬁnition of tumor regression as
the lack of tumor cells and with only ﬁbrous changes present
(total tumor regression), full response to treatment, TRG 4 and
ypT0, was achieved in 30% of the patients. In 50% of the cases,
partial regression was evaluated as Grade 1 and 2 with an
additional examination of tumor features including necrosis,
Fig. 3 – Morphologic characteristics after
radiochemotherapy with isolated tumor cell in the area of
colloid changes.ﬁbrosis, speciﬁc vascular and cellular changes. Tumor regres-
sion grading assessed tumor changes more precisely and did
not correlate with tumor changes evaluated only by the depth
of invasion deﬁned as ypT. Eighty percent of the patients with
pretreatment usN1 and ctN1 regressed to ypNo and in 20%
with usN1 or ctN1 no regression of the metastatic changes in
the lymph nodes was achieved—ypN1.
Following neoadjuvant treatment, full correlation between
TRG 4, full tumor regression and the stage of disease eval-
uated as stage 0 was found, because in all cases with ypT0,
full control was also achieved in the regional lymph nodes
ypN0. In all the caseswithout tumor responseTRG0, ypN1was
observed.
All the patients included in the study were diagnosed as
stage III. The following results from the combined chemo-
radiotherapy and surgical treatment were assessed: 30% of
the cases regressed to stage 0, 20% to stage I, 40% to stage II
and only 10% remained as stage III. Limphovascular invasion
was found in three patients (30%), and full tumor regression
was not achieved in any of those cases and, vise versa, in all
patients with full tumor regression no LVI was observed.
One of the patients (10%) developed severe enterocolitis in
the early and late postoperative period, which was the rea-
son for wound healing by secondary intention and prolonged
hospital stay. No abnormal postoperative complications were
reported in the rest of the cases.
In all specimens, in the tumor area, superﬁcial or deep
ulceration was found, as well as ﬁbrosis of the submucosa,
Fig. 4 – Solitary malignant cell deep in the rectal wall.
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uscle layer and parirectal adipose tissue. Blood vessels
xhibited radiogenic changes in the form of thickening and
brosis of the intima and media, together with thrombotic
bliteration. Vital and necrotic tumor cells were found in the
ymph nodes, with no normal lymph node structure found.
hanges in the lymph node capsule were seen in the form of
brosis, especially in the sinus.
The use of preoperative chemo-radiotherapy modiﬁes the
istologic appearance of rectal cancer (Fig. 2), showing the
eplacement of neoplastic glands by hyaline ﬁbrosis, lack
f tumor necrosis, increased hyperchromasia and nuclear
typia in the present tumor cells. After neoadjuvant treat-
ent tumor cells are replaced by ﬁbrous or ﬁbroinﬂammatory
issue. In the irradiated tissues, hemosiderin-laden (sideroph-
gus) and the so-called “colloid response” or “mucin lakes” are
bserved.
Fibrotic changes are also found in the lymph nodes after
reatment. Diffuse ﬁbrotic changes and sparse lymphoid cells
r focal ﬁbrotic changes with mucinous substance are identi-
ed. Radiation changes are observed in both the capsule and
he lymph node sinus.
. Discussion and conclusion
urrently, there is no standard for pathologic workup of sur-
ical specimen after neoadjuvant treatment. In the case of
visible tumor, a standard pathologic protocol for handling
he material is used, but if there is no visible tumor some
uthors suggest embedding the whole suspicious area and
erforming a thorough search for residual tumor cells. Some
uthors using this technique report ﬁnding vital tumor cells
n all cases after a preoperative treatment.2 Hiotis et al.11 and
hia et al.12 achieved a full histologically proven response
lack of tumor cells) in 10–14% of the patients who under-
ent neoadjuvant treatment, which shows that it is possible
o fully eliminate tumor cells. The high percentage of tumor
ontrol in our study (30%) is connected with the small num-
er of patients included. Picciochi et al.13 did not detect any
umor cells in 15% of studied cases after neoadjuvant treat-
ent. If no tumor cells are identiﬁed on the initial material, it
s recommended to perform further investigation of thewhole
pecimen with additional step sectioning and searching for
umor cell foci. In our study, full tumor control for the primary
umor correlates with tumor control in the regional lymph
odes. In case of suspicion for tumor persistence, imunohisto-
hemical investigation should be performed with antibodies
or cytokeratin.
Some additional characteristics provided by the patholo-
ist correlate with the prognosis of the disease. For example,
ascular invasion of the rectal wall is an unfavorable param-
ter corresponding to a high risk for development of liver
etastases.14 In our investigation, in 2 out of 3 patients
ith LVI, there was no tumor regression after the chemo-
adiotherapy. Ulceration of the peritoneum due to tumor cells
s a poor prognostic sign. Accurate pathomorphologic evalua-
ion of the circumferential resection margins can predict the
isk of local relapse.
The observed colloid changes in resection specimen should
ot to be confused by the pathologist with colloid rectal car-therapy 1 6 ( 2 0 1 1 ) 237–242 241
cinoma. This changes are less basophilic in comparison with
the non-cured colloid carcinoma. The presence ofmucin lakes
dictates a meticulous examination for residual tumor cells
(Fig. 3).
If such cells are identiﬁed, it is possible to ﬁndmore of them
scattered in other parts of the rectal wall or perirectal tissue.
In the case of full regression of superﬁcial lesions, neoplastic
cells can be found deep in the rectal wall (Fig. 4).
The residual malignant cells can acquire eosinophilic
cytoplasm or undergo oncocytic differentiation. The most
common alteration after neoadjuvant chemo-radiotherapy
is eosinophilic cytoplasm due to nuclear atypia. Irradiated
adenocarcinomas can exhibit changes such as neuroen-
docrine differentiation. These changes can be readily
recognized by routine microscopic examination. Neuroen-
docrine cells can be demonstrated by using antibodies to
chromogranin.
The treatment results and insigniﬁcant toxicity prove this
method as a standard in the combined treatment for locally
advanced rectal carcinoma. A longer follow up period and a
larger study with signiﬁcant number of patients is necessary
to ﬁnd the correlation between treatment results andobserved
grades of tumor regression, which assess tumor response
more precisely, compared to the tumor response evaluated
by the change of tumor inﬁltration depth and the changes in
lymph nodes or downsatging.
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